Dr. Xu received his PhD degree in pharmacology from Sun Yat-Sen University (Guangzhou, China) in 2011. After graduation, he did his postdoctoral research at National Heart, Lung and Blood Institute/National Institutes of Health (NHLBI/NIH, Bethesda, MD) as a visiting fellow, studying the biochemistry and function of mono-ADP-ribosyltransferases (ARTs) and poly (ADPribose) polymerases (PARPs). In Feb 2014, he joined the Aab Cardiovascular Research Institute at the University of Rochester (Rochester, NY) as a postdoctoral research associate, studying epigenetic regulation of endothelial function by atheroprotective shear stress and associated vascular biology. He is a member of American Heart Association (AHA, since 2012) and American Association for the Advancement of Science (AAAS, since 2014). He acts as external reviewer for Health and Medical Research Fund (HMRF) of Hong Kong and General Research Fund of Research Grants Council (RGC) of Hong Kong.